EMB-01 is a novel bispecific antibody developed based on EpimAb’s proprietary FIT-Ig® platform to simultaneously target EGFR and cMet on tumor cells. It is being studied in Phase I/II clinical trials in NSCLC as well as several GI indications in the U.S. and China.

EMB-01 is a novel bispecific antibody developed based on EpimAb’s proprietary FIT-Ig® platform to simultaneously target EGFR and cMet on tumor cells. It is being studied in Phase I/II clinical trials in NSCLC as well as several GI indications in the U.S. and China.

EMB-01 is a novel bispecific antibody developed based on EpimAb’s proprietary FIT-Ig® platform to simultaneously target EGFR and cMet on tumor cells. It is being studied in Phase I/II clinical trials in NSCLC as well as several GI indications in the U.S. and China.

EMB-02 is a bispecific antibody targeting human programmed cell death protein 1 (PD-1) and lymphocyte-activation gene 3 (LAG-3) and is being evaluated in advanced solid tumors. This antibody is designed to target human PD-1 and LAG-3 concomitantly or independently and disrupt the immune suppression mediated by both pathways, thereby restoring T-cell effector function and enhancing anti-cancer activity. Currently, a global Phase I/II study is ongoing with sites opened in US, Australia, and China.

EMB-06 is a recombinant humanized bispecific antibody targeted against B cell maturation antigen (BCMA) and cluster of differentiation 3 (CD3). Upon binding to BCMA on tumor cell surface, EMB-06 can recruit and activate CD3 expressing T lymphocytes, thereby mediating the killing effect of T lymphocytes on tumor cells. Currently, a global Phase I/II study is enrolling patients in Australia and China.

EMB-09 is a novel bispecific antibody developed based on EpimAb’s proprietary FIT-Ig® platform to block PD-1/PD-L1 inhibitory signaling, and conditionally activate T effector cells by stimulating OX40 through PD-L1 dependent cross linking. EMB-09 showed superior immune cell activation in comparison with the mAb combinations. Its unique OX40 binding epitope could improve the therapeutic window, and silenced Fc effector function can avoid T effector cell depletion.

EMB-07 is a T cell redirecting bispecific antibody by targeting a novel tumor associated antigen (TAA) and cluster of differentiation 3 (CD3). EMB-07 is designed based on EpimAb’s proprietary bispecific antibody platform. Upon binding to TAA on the tumor cell surface, EMB-07 can recruit and activate CD3 expressing T lymphocytes, thereby promoting the cytotoxic effect of T lymphocytes. EMB-07 showed a promising preclinical efficacy and safety profile. IND submission is expected in 2022.